Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Nice to see today’s Mirimus thread highlights this thread from yesterday.
https://www.pharmavoice.com/news/covid-mystery-gene-therapy/704683/
A shifting biotech focus in infectious disease
The Brooklyn biotech company Mirimus, for instance, is developing a test to screen for the autoantibodies that can contribute to severe COVID infection, potentially helping those at risk take needed precautions, and better monitor and treat the infection if they get sick.
“That is a sign that at least some companies are understanding what’s going on,” Casanova said. ”
Thanks Brand
It will be interesting to see who they partner with in manufacture as that may well be the link into Synairgen.
I’m pretty sure Casanova only license so we have another dependency in our trial deliverable which may well explain why H2 2023 did not happen.
That will obviously be part of a non disclosure agreement until parties agree otherwise.
Jean-Laurent Casanova is the Levy Family Professor at The Rockefeller University
He has identified single-gene inborn errors of type I and type II IFN immunity, as well as auto-antibodies neutralizing type I and type II IFNs, which respectively underlie viral and intra-macrophagic infections. Jean-Laurent became an Academic Editor of the Journal of Experimental Medicine in 2006.
Scientific advisory boards/consulting: ADMA, Celgene, Elixiron Immunotherapeutics, KymeraTX,
“Mirimus”
Patent applications: Inventor on a pending patent application that covers diagnosis of susceptibility to, and treatment of, viral disease and viral vaccines, including Covid-19 and vaccine-associated diseases. This pending patent application is currently not licensed.
Jean-Laurent Casanova is the Levy Family Professor at The Rockefeller University
He has identified single-gene inborn errors of type I and type II IFN immunity, as well as auto-antibodies neutralizing type I and type II IFNs, which respectively underlie viral and intra-macrophagic infections. Jean-Laurent became an Academic Editor of the Journal of Experimental Medicine in 2006.
Scientific advisory boards/consulting: ADMA, Celgene, Elixiron Immunotherapeutics, KymeraTX,
Mirimus.
Https://www.medrxiv.org/content/10.1101/2020.10.18.20214783v1
2.5 Million Person-Years of Life Have Been Lost Due to COVID-19 in the United States
Stephen J Elledge founder of Mirimus
Interesting guy with lots of links into NIH, Casanova immune research
Https://www.mirimus.com/clinicaltesting
Protecting yourself against COVID-19 is more than just getting vaccinated. Immune Index™ is the ultimate clinical tool for monitoring your immune status against COVID-19 in real-time. With just a simple finger prick, you can get highly accurate results on your neutralizing antibodies, helping you make informed decisions regarding vaccination and close-contact exposure. Our cutting-edge technology provides doctors and patients with a wealth of valuable information, including advising individuals to receive vaccination booster in high-risk groups, or defer in high immunity cases to minimize the risk of complications. With regular monitoring every 6 months, Immune Index™ supports optimal management of patient care.
Our cancer tumour genome guy has an interesting affiliation Gunto to your post
Dr. Lowe is a scientific consultant and holds equity in Blueprint Medicines, Constellation Pharmaceuticals, Faeth Therapeutics, “Mirimus” , ORIC Pharmaceuticals, and PMV Pharmaceuticals
TP
I suggest people look at your posting history and see how many times you trivialize my research or others including pretending we work for Synairgen.
Take a long hard look in the mirror and come backward with some research instead of deriding other people’s
Doc D TP
I think you protest too much after TP posted this this morning
“The purists here, who derive interim satisfaction from Dr.Monk’s joint publications with a host of others, and peripheral information tentatively linked to Synairgen are a breed apart”
If anyone starts bad feelings on this board it’s you two
TP
Perhaps if you spent half the time you do on this board endlessly repeating the same 23 months theme and actually did some research. We would all benefit.
But I’m not going to join in Yours and Doc D bating
Have a nice day